GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » EV-to-EBITDA

TELO (Telomir Pharmaceuticals) EV-to-EBITDA : -5.07 (As of May. 23, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Telomir Pharmaceuticals's enterprise value is $63.49 Mil. Telomir Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-12.53 Mil. Therefore, Telomir Pharmaceuticals's EV-to-EBITDA for today is -5.07.

The historical rank and industry rank for Telomir Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

TELO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.07   Med: 0   Max: 0
Current: -5.07

TELO's EV-to-EBITDA is ranked worse than
100% of 501 companies
in the Biotechnology industry
Industry Median: 7.89 vs TELO: -5.07

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-23), Telomir Pharmaceuticals's stock price is $2.20. Telomir Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.420. Therefore, Telomir Pharmaceuticals's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Telomir Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Telomir Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals EV-to-EBITDA Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
- - - -9.95

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.60 -10.91 -10.56 -9.95 -7.64

Competitive Comparison of Telomir Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Telomir Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telomir Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telomir Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Telomir Pharmaceuticals's EV-to-EBITDA falls into.


;
;

Telomir Pharmaceuticals EV-to-EBITDA Calculation

Telomir Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=63.494/-12.526
=-5.07

Telomir Pharmaceuticals's current Enterprise Value is $63.49 Mil.
Telomir Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telomir Pharmaceuticals  (NAS:TELO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Telomir Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.20/-0.420
=At Loss

Telomir Pharmaceuticals's share price for today is $2.20.
Telomir Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.420.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Telomir Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Telomir Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
100 South East, 2nd Street, Suite 200, No.1009, Miami, FL, USA, 33131
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.

Telomir Pharmaceuticals Headlines

From GuruFocus